BridgeBio Oncology Therapeutics(BBOT)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: BridgeBio Oncology Therapeutics is a public biotechnology company focused on RAS-targeted small molecule therapeutics for solid tumors and non-small cell lung cancer. The company is in early-stage development with a lean, focused pipeline.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
9+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at BridgeBio Oncology Therapeutics?
AI assessmentBest suited for early-stage oncology specialists willing to accept pre-revenue execution risk in exchange for meaningful early-development influence and equity upside.
Why Work Here
- Early-stage oncology focus with three Phase 1 programs targeting high-value RAS mutations, offering opportunity to shape clinical strategy from the ground up.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Help build intelligence for BridgeBio Oncology Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.